CBD vs. Melatonin for Sleep: What the Research Shows

Sleep gummies often carry melatonin, CBD or both. Here is what the research shows for each. We do not recommend products, brands or doses.

At a glance

What melatonin and CBD are

Melatonin is a hormone your brain produces in response to darkness that helps time your 24-hour internal clock and sleep (NCCIH 2024). In the US it is sold as a dietary supplement, regulated less strictly than prescription or over-the-counter drugs; several other countries require a prescription (NCCIH 2024). Under federal supplement law (DSHEA, 1994), the FDA cannot approve supplements or their labels for safety and effectiveness before they are sold; companies are responsible for their products' safety (FDA 2022).

CBD (cannabidiol) is a compound from the cannabis plant that does not cause a high (Gournay 2026; what is CBD oil?). The FDA has approved one CBD medicine, Epidiolex, and has concluded that CBD products cannot be sold as dietary supplements (FDA 2024; is CBD FDA approved?).

Melatonin and sleep: what the research shows

• Falling asleep in general: A meta-analysis (a study pooling other studies) of 19 placebo-controlled trials with 1,683 adults and children with primary sleep disorders found melatonin shortened the time to fall asleep by about 7 minutes and added about 8 minutes of total sleep. The authors called the effects "modest" (Ferracioli-Oda 2013).
• Chronic insomnia: The American Academy of Sleep Medicine (AASM) suggests that clinicians not use melatonin for trouble falling or staying asleep in adults with chronic insomnia (a "weak" recommendation). It is based on three trials of 2 mg prolonged-release melatonin (study dose) in adults over 55, and the guideline rates that evidence as very low quality (Sateia 2017).

Strength of evidence: moderate that the effect on falling asleep is real but small; very low for chronic insomnia.

• Jet lag: In a Cochrane review, 9 of 10 trials found that melatonin taken close to bedtime at the destination reduced jet lag after flights crossing five or more time zones. Taken at the wrong time of day, it could cause sleepiness and slow adjustment (Herxheimer 2002).
• A "late" body clock (delayed sleep phase): In a meta-analysis of 9 trials (91 adults, 226 children), melatonin moved sleep onset about 40 minutes earlier and cut the time to fall asleep by about 23 minutes; wake-up time and total sleep did not change (van Geijlswijk 2010). The AASM gives strategically timed melatonin a weak ("second-tier") endorsement for this condition (Auger 2015).

Strength of evidence: low to moderate for jet lag — one 2002 Cochrane review of small trials, not updated since, found a consistent benefit; a 2006 meta-analysis found no effect on time to fall asleep in jet lag and shift work (Buscemi 2006). Low to moderate for delayed sleep phase (nine small trials).

Short-term side effects reported with melatonin were mild, such as headache, dizziness, nausea and sleepiness; long-term safety is unclear (NCCIH 2024). Strength of evidence: low for long-term safety, which has not been studied well.

CBD and sleep: what the research shows

CBD sleep research is newer and smaller.

• Insomnia: In 30 adults with moderate-to-severe insomnia, 150 mg of CBD (study dose) or placebo nightly for two weeks made no difference in insomnia severity, time to fall asleep or time awake at night. The CBD group reported greater well-being and had better sleep efficiency measured by a wrist device at week two, although self-reported sleep efficiency did not differ (Narayan 2024).
• High worry: In 63 adults, 300 mg of CBD a day (study dose) for two weeks reduced sleep problems more than 50 mg, but not significantly more than placebo (Gournay 2026).
• Healthy sleepers: A single 300 mg dose (study dose) had no significant effect on lab-measured sleep in 27 healthy volunteers (one withdrew) (Linares 2018).
• Pooled results: A 2025 meta-analysis of six trials found CBD-only treatments did not significantly improve sleep quality versus placebo; the significant effect came from products other than CBD alone (da Silva 2025). A 2026 Cochrane review of medical cannabis preparations for insomnia (nine trials) found they may have little to no meaningful effect on sleep quality or total sleep, with very low certainty of evidence (Varela 2026).

Strength of evidence: low. A few small, short trials; for pure CBD, the main sleep measures did not differ from placebo. Details are on our insomnia page.

CBD vs. melatonin: the one head-to-head trial

The only randomized trial we found comparing them gave 1,793 adults with sleep problems capsules with 15 mg of CBD or 5 mg of melatonin (study doses), alone or with other cannabinoids, for four weeks; they rated their sleep in weekly online surveys. Every group improved, with no significant difference between CBD and melatonin (Saleska 2024). But there was no placebo group, so the trial cannot show that either beat a dummy pill, and four of the eight authors listed a private research company as their affiliation (Saleska 2024).

Strength of evidence: low. One trial, self-reported outcomes, no placebo group.

Is what's on the label what's inside?

• Melatonin gummies: Of 25 products bought online in the US, 22 (88%) were mislabeled; in those that contained melatonin, the amount ranged from 74% to 347% of the label. One contained no detectable melatonin but 31.3 mg of CBD per serving (Cohen 2023).
• CBD extracts: Of 84 products bought online in 2016, only 31% had CBD within 10% of the label; 43% had more and 26% had less. THC was found in 21% (Bonn-Miller 2017).

Strength of evidence: moderate for these specific samples; each is a single snapshot of products from one year. See our label reading guide; THC can also matter for drug tests.

Children: melatonin vs. CBD

Melatonin. From 2012 to 2021, 260,435 melatonin ingestions by children and teens were reported to US poison centers, and the yearly number rose 530%. Most (94.3%) were unintentional and most children (84.4%) had no symptoms, but 4,097 were hospitalized and 287 needed intensive care; most hospitalized patients were teens with intentional ingestions (Lelak 2022). The CDC later estimated about 11,000 emergency visits in 2019–2022 for unsupervised ingestion by children 5 and under, often of gummies; as of the CDC's 2024 report, melatonin products were not required to have child-resistant packaging (Freeman 2024).

Strength of evidence: surveillance data. It clearly shows a rise in accidental ingestions, not how often melatonin harms a child who uses it.

The AASM advises treating melatonin like any medicine, keeping it out of children's reach, and talking with a pediatric health care professional first; many sleep problems "can be better managed with a change in schedules, habits, or behaviors rather than taking melatonin" (AASM 2022). Long-term effects in children, including on puberty, are not known (NCCIH 2024). Source type: AASM health advisory (position statement); NIH guidance.

CBD. The only CBD product approved for children is Epidiolex, a prescription medicine for seizures in Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex, from age 1 (DailyMed 2026). The FDA has approved only one cannabis-derived drug (Epidiolex) and three cannabis-related drugs, all prescription-only, and warns that for children "the use of untested drugs can have unpredictable and unintended consequences" (FDA 2024). In a November 2026 PubMed search, we found no randomized trial of CBD as a sleep aid in otherwise healthy children. More: drug-resistant epilepsy.

Source type: FDA drug label and FDA guidance page (final).

Taking CBD and melatonin together

We found no study in people that measured what CBD does to melatonin levels.

• A shared enzyme: The body breaks down melatonin mainly through the liver enzyme CYP1A2 (Papagiannidou 2014). The Epidiolex label calls CBD a weak CYP1A2 inhibitor: at 750 mg twice daily (prescription study dose), it nearly doubled exposure to caffeine, which the same enzyme breaks down (+95%) (DailyMed 2026).
• Lab and animal data: In human liver preparations, CBD slowed melatonin breakdown, but in cell tests it also reduced melatonin uptake. In dogs it raised melatonin levels, while in rats the effect changed with dose. The researchers' model projected a worst-case rise in melatonin exposure of up to 12 times in people; that is a projection, not a measurement (Zheng 2025).
• Extra drowsiness: Sleepiness is a side effect of melatonin (NCCIH 2024). In Epidiolex trials for Lennox-Gastaut and Dravet syndromes, at prescription doses, sleepiness and sedation affected 32% of patients versus 11% on placebo, and the label warns that other sedating substances, including alcohol, may add to it (DailyMed 2026).
• No added benefit shown: In the head-to-head trial, melatonin combined with CBD and CBN did no better than CBD alone (Saleska 2024).

Strength of evidence: very low; the interaction concern comes from lab, animal and high-dose label data. Check your medicines with our CBD drug interaction checker.

The first-line treatment for insomnia isn't a supplement

The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as the first treatment for all adults with chronic insomnia (strong recommendation, moderate-quality evidence) (Qaseem 2016). The AASM also strongly recommends multicomponent CBT-I (Edinger 2021). CBT-I usually takes 6 to 8 weeks, in person, by phone or online, and combines cognitive therapy (easing worry about sleep), relaxation, sleep education, a set time in bed, and retraining the link between bed and sleep (NHLBI 2022).

Strength of evidence: moderate, as graded by the American College of Physicians.

When to talk to a doctor or pharmacist

• Sleep trouble lasting a month or longer, the point at which insomnia is called chronic (NCCIH 2024).
• Signs of sleep apnea: loud snoring, breathing that stops and starts, gasping for air, or daytime sleepiness; a sleep study may be needed (NHLBI 2025).
• Before giving melatonin or CBD to a child (AASM 2022; FDA 2024). If a child swallows gummies not meant for them, contact a poison center or emergency services.
• If you take medicines, have epilepsy, use a blood thinner, or are pregnant or breastfeeding. People with epilepsy or on blood thinners need medical supervision with melatonin, and its safety in pregnancy has not been well studied (NCCIH 2024).

Frequently asked questions

References